Glenmark gets approval from Australian regulator to commercialise Ryaltris

Glenmark gets approval from Australian regulator to commercialise Ryaltris Ryaltris is a new fixed dose combination nasal spray of an antihistamine and a steroid indicated for treatment of symptoms associated with allergic rhinitis and rhinoconjunctivitis in patients over 12 years of age in Australia.

No comments:

Post a Comment